Centessa Pharmaceuticals

CNTA

Valor de mercado US$ 6,27 bi

BOSTON and LONDON, June 22, 2026 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage company developing a new class of medicines for the treatment of excessive daytime sleepiness and other neurological conditions, which entered into a definitive agreement on March 31, 2026 relating to its proposed acquisition by Eli Lilly and Company (“Lilly”), through a wholly owned subsidiary, today announced that the High Court of Justice of England and Wales has approved the proposal for Lilly to acquire Centessa for $38.00 in cash per share plus one non-transferable contingent value right (“CVR”) that entitles the holder to receive up to an aggregate of $9.00 subject to the achievement of three milestones, for a total transaction value of approximately $7.8 billion (the “Transaction”).

Proven Chief Medical Officer at several publicly listed and clinical-stage oncology companies with successful track record developing multiple modalities including radiotherapies from preclinical through global approvals across hematologic malignancies and solid tumors Played a leading role in clinical development and worldwide approvals of Erbitux® at Merck KGaA leading to its blockbuster status Led clinical development as CMO of NBE Therapeutics which was acquired by Boehringer Ingelheim for $1.4 billion, and most recently CMO of radiotherapy company Full-Life Technologies Timely key hire with Dr. Heeger's operational rigor and clinical expertise expected to elevate development of Actimab-A, ATNM-400, and Iomab-ACT as Actinium advances toward key data readouts and expanded clinical trials in 2H:2026 NEW YORK, June 1, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced the appointment of Steffen Heeger, MD, MSc, as Chief Medical Officer. Dr. Heeger brings a rare combination of radiotherapy expertise, global oncology drug development leadership, and public-company experience.

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Centessa Pharmaceuticals plc (NasdaqGS: CNTA) to Eli Lilly and Company (NYSE: LLY). Under the terms of the proposed transaction, shareholders of Centessa will receive $38.00 in cash per share plus one non-transferrable contingent value right entitling the holder to receive up to an aggregate of.

MILWAUKEE, April 07, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Centessa (NASDAQ: CNTA) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Lilly.

NEW YORK, April 1, 2026 /PRNewswire/ -- Class Action Attorney  Juan Monteverde  with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Centessa Pharmaceuticals plc (NASDAQ: CNTA) related to its sale to Eli Lilly and Company.

Lilly is set to acquire Centessa for up to $7.8B, adds sleep disorder drugs and advances its push to diversify beyond obesity and diabetes treatments.

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Centessa Pharmaceuticals plc (NasdaqGS: CNTA) to Eli Lilly and Company (NYSE: LLY). Under the terms of the proposed transaction, shareholders of Centessa will receive $38.00 in cash per share plus one non-transferrable contingent value right entitling the holder to receive up to an aggregate of.

Centessa possesses a promising sleep medicine pipeline. The clinical-stage company's experimental therapies have blockbuster potential.

Tokyo, Japan and Cambridge, UK, 1 April 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that its partner, Centessa Pharmaceuticals Limited (“Centessa”), has announced that it entered into a definitive agreement regarding its acquisition by Eli Lilly and Company (“Lilly”) on 31 March 2026 (US local time).

Eli Lilly has agreed to acquire Centessa Pharmaceuticals in a deal valued at up to $7.8 billion, marking a significant expansion of the drugmaker's neuroscience portfolio into sleep medicine. Under the terms announced Tuesday, Lilly will pay $38 per share in cash upfront, valuing Centessa at approximately $6.3 billion.